Q1 EPS Estimates for HealthEquity Lowered by Zacks Research

HealthEquity, Inc. (NASDAQ:HQY) – Stock analysts at Zacks Research decreased their Q1 2026 earnings estimates for HealthEquity in a research report issued to clients and investors on Tuesday, April 8th. Zacks Research analyst R. Department now forecasts that the company will post earnings of $0.63 per share for the quarter, down from their previous estimate of $0.68. The consensus estimate for HealthEquity’s current full-year earnings is $2.32 per share. Zacks Research also issued estimates for HealthEquity’s Q2 2026 earnings at $0.72 EPS, Q3 2026 earnings at $0.72 EPS, Q4 2026 earnings at $0.85 EPS, FY2026 earnings at $2.90 EPS, Q1 2027 earnings at $0.76 EPS, Q2 2027 earnings at $0.94 EPS, Q3 2027 earnings at $0.93 EPS, Q4 2027 earnings at $1.03 EPS and FY2027 earnings at $3.66 EPS.

A number of other equities research analysts also recently issued reports on HQY. Raymond James raised shares of HealthEquity from an “outperform” rating to a “strong-buy” rating and cut their price objective for the company from $120.00 to $115.00 in a research report on Tuesday, March 25th. The Goldman Sachs Group decreased their price objective on HealthEquity from $107.00 to $94.00 and set a “neutral” rating on the stock in a research note on Thursday, March 27th. Wells Fargo & Company boosted their price objective on HealthEquity from $110.00 to $125.00 and gave the company an “overweight” rating in a research note on Wednesday, February 26th. KeyCorp reduced their target price on shares of HealthEquity from $120.00 to $110.00 and set an “overweight” rating for the company in a report on Monday, March 24th. Finally, Barrington Research reaffirmed an “outperform” rating and set a $112.00 price target on shares of HealthEquity in a report on Friday, March 14th. One analyst has rated the stock with a hold rating, ten have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, HealthEquity currently has an average rating of “Buy” and an average price target of $112.58.

HealthEquity Price Performance

NASDAQ HQY opened at $79.94 on Friday. The company has a debt-to-equity ratio of 0.51, a quick ratio of 3.20 and a current ratio of 3.20. HealthEquity has a one year low of $65.01 and a one year high of $115.59. The company has a market capitalization of $6.91 billion, a price-to-earnings ratio of 73.34, a PEG ratio of 1.60 and a beta of 0.49. The stock has a 50-day moving average of $98.22 and a 200 day moving average of $96.27.

Institutional Trading of HealthEquity

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Wealthfront Advisers LLC bought a new position in HealthEquity in the 4th quarter valued at $10,304,089,000. T. Rowe Price Investment Management Inc. bought a new position in shares of HealthEquity in the fourth quarter worth about $78,107,000. Norges Bank purchased a new position in HealthEquity in the 4th quarter worth about $74,701,000. Raymond James Financial Inc. purchased a new stake in HealthEquity in the 4th quarter valued at about $45,728,000. Finally, Iron Triangle Partners LP purchased a new stake in shares of HealthEquity in the fourth quarter valued at approximately $32,202,000. 99.55% of the stock is owned by hedge funds and other institutional investors.

Insider Activity

In other HealthEquity news, Director Robert W. Selander sold 5,750 shares of the business’s stock in a transaction that occurred on Monday, February 10th. The stock was sold at an average price of $111.29, for a total transaction of $639,917.50. Following the sale, the director now directly owns 78,219 shares of the company’s stock, valued at $8,704,992.51. The trade was a 6.85 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, EVP Michael Henry Fiore sold 8,881 shares of the firm’s stock in a transaction that occurred on Friday, April 4th. The shares were sold at an average price of $78.26, for a total value of $695,027.06. Following the completion of the sale, the executive vice president now directly owns 56,655 shares of the company’s stock, valued at $4,433,820.30. The trade was a 13.55 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 2.20% of the company’s stock.

About HealthEquity

HealthEquity, Inc provides technology-enabled services platforms to consumers and employers in the United States. The company offers cloud-based platforms for individuals to make health saving and spending decisions, pay healthcare bills, receive personalized benefit information, earn wellness incentives, grow their savings, and make investment choices; and health savings accounts.